Postpartum ASA and NT-proBNP

• Status: Not yet recruiting
• Trial end date: 2024-10-01
• Target enrollment: 0
• Participant gender: Female

Summary

This study is a double-blinded randomized-controlled trial in which patients will be randomized to 81 mg of aspirin or placebo to be continued for 6 weeks' postpartum. The purpose of this study is to compare NT-proBNP levels at the 4-6 week postpartum visit between groups. There is currently no data on the maternal health effects associated with continuation of low-dose aspirin in the postpartum period. This study aims to fill a gap in the knowledge regarding the utility of low-dose aspirin following delivery.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Duke University
• Treatments: Aspirin

Criteria

Inclusion Criteria:

• 18 years of age and older

• English-speaking

• postpartum

• have met USPSTF recommendations for low-dose aspirin use during pregnancy: >1 high risk factor (history of preeclampsia in prior pregnancy, multifetal gestational, chronic hypertension, preexisting diabetes, renal disease, autoimmune disease) or >2 moderate risk factors (nulliparity, obesity, family history of preeclampsia, sociodemographic characteristics, age 35 years or older, or personal history factors) and reported at least 50% compliance with aspirin during pregnancy.

Exclusion Criteria:

• hypersensitivity reaction to aspirin or other salicylates,

• history of gastrointestinal bleeding

• history of gastric or duodenal ulcers

• severe hepatic dysfunction

• bleeding disorders and diathesis

• known cardiac dysfunction with reduced ejection fraction, or are taking or prescribed ACE inhibitors.

• Patients who required ICU level care during their pregnancy will be excluded.